RYTM in the 13F filings
Rhythm Pharmaceuticals Inc · CUSIP 76243J105
- Quarter end
- 31 Mar 2025
- the date the book describes
- Filed
- 15 May 2025
- latest of these filings; the earliest 15 May 2025
- Managers listing it
- 4
- at least, of 95 tracked, among listed positions
- Comparable managers
- 95
- filed both Q4 2024 and Q1 2025; 4 listed it in both
- Shares listed
- 2,715,516
- combined, among listed positions
- Reported value
- $147m
- combined, at the quarter end
Among the 95 comparable managers: 3 buyers (opened or added shares) and 1 seller (trimmed or exited), at least, among listed positions. Their net change in shares was +379,039.
Managers listing RYTM in Q1 2025
4 of 4 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| Janus Henderson Group Ltd | 1,655,350 | $91m | under 0.1% | Added | +435,796 | 15 May 2025 (the filing on sec.gov) |
| Marshall Wace LLP | 535,103 | $28m | under 0.1% | Trimmed | -157,700 | 15 May 2025 (the filing on sec.gov) |
| Voloridge Investment Management LLC | 422,868 | $22m | 0.08% | Added | +42,331 | 15 May 2025 (the filing on sec.gov) |
| PDT Partners LLC | 102,195 | $5.4m | 0.38% | Added | +58,612 | 15 May 2025 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
- Janus Henderson Group Ltdexisting position · 1,655,350 shares now+435,796
- PDT Partners LLCexisting position · 102,195 shares now+58,612
- Voloridge Investment Management LLCexisting position · 422,868 shares now+42,331
Reductions
- Marshall Wace LLPexisting position · 535,103 shares now-157,700
New positions and exits
New (0)
No new position among listed positions.
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2018 | 1 | $750k | n.a. | n.a. |
| Q2 2018 | 3 | $76m | n.a. | n.a. |
| Q3 2018 | 3 | $91m | n.a. | n.a. |
| Q4 2018 | 1 | $88m | n.a. | n.a. |
| Q1 2019 | 2 | $90m | n.a. | n.a. |
| Q2 2019 | 1 | $72m | n.a. | n.a. |
| Q3 2019 | 1 | $74m | n.a. | n.a. |
| Q4 2019 | 1 | $99m | n.a. | n.a. |
| Q1 2020 | 1 | $66m | n.a. | n.a. |
| Q2 2020 | 1 | $98m | n.a. | n.a. |
| Q3 2020 | 1 | $95m | n.a. | n.a. |
| Q4 2020 | 1 | $134m | n.a. | n.a. |
| Q1 2021 | 1 | $87m | n.a. | n.a. |
| Q2 2021 | 1 | $77m | n.a. | n.a. |
| Q4 2021 | 1 | $593k | n.a. | n.a. |
| Q1 2022 | 1 | $474k | n.a. | n.a. |
| Q2 2022 | 1 | $628k | n.a. | n.a. |
| Q3 2022 | 2 | $43m | n.a. | n.a. |
| Q4 2022 | 1 | $36m | n.a. | n.a. |
| Q3 2023 | 3 | $33m | n.a. | n.a. |
| Q4 2023 | 4 | $61m | 3 | 1 |
| Q1 2024 | 3 | $40m | 2 | 0 |
| Q2 2024 | 4 | $32m | 1 | 3 |
| Q3 2024 | 6 | $80m | 4 | 3 |
| Q4 2024 | 4 | $131m | 4 | 1 |
| Q1 2025 | 4 | $147m | 3 | 1 |
| Q2 2025 | 5 | $160m | 2 | 3 |
| Q3 2025 | 9 | $496m | 7 | 2 |
| Q4 2025 | 10 | $537m | 16 | 16 |
| Q1 2026 | 7 | $450m | 18 | 14 |
| Q2 2026 | 9 | $859m | 14 | 18 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
RYTM and LLY →RYTM and JNJ →RYTM and VRTX →Choose a stock to compare with RYTM →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own RYTM, latest filings →Back to the 13F Explorer →